UCL Global


Hybrid Fe@FexOy@Alendronate Nanoparticles

Developing Nanoparticles as Multimodal MRI/ Chemotherapy/ Magnetic Hyperthermia Therapy agents for combined cancer treatment. Part of the Cities partnership Programme.

13 September 2022

Our research aims to collaboratively develop a very innovative multimodal nanomaterial for cancer therapy.  Experiments carried out at UCL and The University of Paris 13 (UP13) will synthesise Fe@FexOy nanoparticles, before assessing their surface functionalisation. This, in turn, will allow us to evaluate the agent’s properties for combined cancer treatment in vitro, an experiment which will take place both at UCL and UP13. The data from this will be collated and published in papers and reports, as well as a set of lectures and seminars. 



UCL leads

Partner leads

LUISS Guido Carli

  • Alessandro Zattoni
  • Francesco Rullani
  • Andrea Prencipe